Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Background Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse.Methods This study assessed 5-ye...
Saved in:
Similar Items
-
Sex Determination in Reptiles: A Review
by: Alessandro Vetere, et al.
Published: (2025-01-01) -
Pericapsular nerve group block and lateral femoral cutaneous nerve block versus fascia iliaca block for multimodal analgesia after total hip replacement surgery: A retrospective analysis; Reply to Gupta et al.
by: Alessandro Girombelli, et al.
Published: (2025-01-01) -
Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials
by: Stefano Marini, et al.
Published: (2016-01-01) -
0.5 V Digitally-Tunable Filters for Biomedical Applications Exploiting Segmented Duty-Cycled Resistors
by: Alessandro Fava, et al.
Published: (2025-01-01) -
Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
by: Federica Toscanini, et al.
Published: (2011-01-01)